Patients with Resected Node-Positive or High-Risk Node-Negative HER2-Negative, ER- and PgR-Negative* Invasive Breast Cancer

**STRATIFICATION**
- Number of positive nodes (0, 1–3, 4–9, 10+)
- *BRCA* mutation status (positive; negative or unknown)

**RANDOMIZATION**

**Arm 1**
AC→WP**

**Arm 2**
AC→WP + Carboplatin***

---

* Patients are eligible if the tumor staining meets one of the following criteria:
  - ER-negative and PgR-negative by ASCO/CAP guidelines, OR
  - ER or PgR stains are positive in 1-9% of cells and neither is positive in ≥ 10% of cells.

** Chemotherapy regimen for Arm 1**
AC→ Weekly Paclitaxel (WP): Doxorubicin (A) 60 mg/m² IV + cyclophosphamide (C) 600 mg/m² IV every 2 weeks for 4 cycles (dose-dense schedule) followed by paclitaxel 80 mg/m² IV weekly for 12 doses.

*** Chemotherapy regimen for Arm 2**
AC→ Weekly Paclitaxel (WP) + Carboplatin: Doxorubicin (A) 60 mg/m² IV + cyclophosphamide (C) 600 mg/m² IV every 2 weeks for 4 cycles (dose-dense schedule) followed by paclitaxel 80 mg/m² IV weekly for 12 doses plus carboplatin AUC of 5 IV every 3 weeks for 4 cycles.